Cargando…
Bradycardia and Hypothermia Complicating Azithromycin Treatment
Patient: Male, 4 Final Diagnosis: Febrile neutropenia Symptoms: Fever Medication: Azithromycin Clinical Procedure: — Specialty: Infectious Diseases OBJECTIVE: Unusual or unexpected effect of treatment BACKGROUND: Azithromycin is a macrolide antibiotic widely used to treat respiratory, urogenital, an...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562267/ https://www.ncbi.nlm.nih.gov/pubmed/28798290 http://dx.doi.org/10.12659/AJCR.905400 |
Sumario: | Patient: Male, 4 Final Diagnosis: Febrile neutropenia Symptoms: Fever Medication: Azithromycin Clinical Procedure: — Specialty: Infectious Diseases OBJECTIVE: Unusual or unexpected effect of treatment BACKGROUND: Azithromycin is a macrolide antibiotic widely used to treat respiratory, urogenital, and other infections. Gastrointestinal upset, headache, and dizziness are common adverse effects, and prolongation of the rate-corrected electrocardiographic QT interval and malignant arrhythmias have been reported. There are rare reports of bradycardia and hypothermia but not in the same patient. CASE REPORT: A 4-year-old boy given intravenous azithromycin as part of treatment for febrile neutropenia complicating leukemia chemotherapy developed hypothermia (rectal temperature 35.2°C) and bradycardia (65 beats/minute) after the second dose, which resolved over several days post-treatment, consistent with persistence of high tissue azithromycin concentrations relative to those in plasma. A sigmoid E(max) pharmacokinetic/pharmacodynamic model suggested a maximal azithromycin-associated reduction in heart rate of 23 beats/minute. Monitoring for these potential adverse effects should facilitate appropriate supportive care in similar cases. CONCLUSIONS: Recommended azithromycin doses can cause at least moderate bradycardia and hypothermia in vulnerable pediatric patients, adverse effects that should prompt appropriate monitoring and which may take many days to resolve. |
---|